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Abstract 
Estradiol hormones will increase the risk for breast cancer. About 5% to 10% of breast cancer patients bring 
with them germ line mutation. The aim of this study is to evaluate the estradiol and HDL-cholesterol levels and 
the correlation with BRCA1 gene C61G mutation. This research included 120 blood samples from normal 
females and 45  tissue samples.  The results were that subjects with breast cancer in premenopause group 
indicating higher estradiol levels compared with menopause group. Highest HDL-cholesterol levels were found 
in 30-39 year group, and the lowest levels were found in the 50-59 years old group. Of all subject, only 32,5% 
samples with ER+/PR+, while ER-/PR- were found in 37,5%.  HER-2/neu(+3) was found in 55,5% samples. For 
ER+/PR+ increased in the age group of 40-49 years, while ER-/PR- increased in the age group of 40-49 years  ( 
pre-menopause > menopause ).  HER2/neu (+3) was higher in pre-menopause  than in menopause group.  DNA 
sequencing results with no mutation or polymorphism in this SNP. There was significant difference between 
pre-menopause group and menopause group in estradiol and HDL-cholesterol content, ER+/PR+ was highest in 
pre-menopause.  
------------------------------------------------------------------------ 
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The highest  ER-/PR- was found in in pre-menopause group, and the highest Her2/neu (+) was found in pre-
menopause. BRCA1 gene C61G mutation was not found, it was suggested that polymorphism is occured in 
another different location.   
Keywords: Estradiol; HDL cholesterol; ER/PR; HER2/neu; BRCA1 mutation C61G. 
1. Background 
Some risk factors are related to the increase in the case of breast cancer, including genetics, and history of 
reproduction [1]. Seventy five percents of all women with breast cancer do not know about its risk factors, and 
not all of them who are affected by breast cancer have the same risk factors. Some of these risk factors are not 
reversible .  The increase in the exposure to estrogenic hormone will cause the increase in the risk for the 
incidence of breast cancer [2,3]. 
Germ line of BRCA1 gene mutation is about 40%-45% of the number of breast cancers which can be decreased, 
and every family member has high incidence in breast cancer. In this research, the evaluation on BRCA1 Gene 
mutation to C61G and the influence of another hormonal risk factors of breast cancer were performed. 
2. Method  
This research was conducted in Hospital Prima Medan, north sumatra, Indonesia. 
HDL-cholesterol levels was determined by using method [3]. 
DNA sequensing was performed at laboratory of Biomedical Science, Medical Faculty, Andalas University, 
Padang, Indonesia in the period of 2016-2017.   
Age Group of  < 50 years  and > 50 years old. Group I, 30 – 39 years  Group  II, 40 – 49 years   Group III, 50 – 
59 years Group IV,>  60 years 
3. Devices and Material  
The material used for isolating DNA from the blood was blood DNA isolating kits (PureLink Genomic DNA 
Mini Kit Invitrogen #Cat:K1820-01).  
Polymerase Chain Reaction (PCR) 
DNA genome was obtained by isolation using PCR technique. The quality of DNA as the result of amplification 
with PCR technique was seen by using agarose gel electrophoresis technique [4,5]. 
Detecting C61G Polymorphism with PCR Sequencing Method  
BRCA1 gene polymophism in C61G allele was determined by analyzing PCR sequencing. The data of the 
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sequencing result was then processed by using Genious software (contig. alignment, and multiple alignments) in 
order to obtain SNP maturation of C61G allele.    
Procedure  
Blood samples were taken through antecubital vein function of 2 ml which was put into a tube containing 
ethylene diamine tetra acid (EDTA) anticoagulants in which DNA and PCR were extracted.  
Blood DNA isolation procedure performed as the instructions of the protocol of using DNA Invitrogen isolation 
kit.  
Specific Primer Design 
Table 1: Primer Pair Used to Identify C61G Allele Polymorphism 
Primer  Sequence  
Forward  
Reverse 
5’- CTC TTA AGG GCA GTT GTG AG -3’ 
5’- TTC CTA CTG TGG TTG CTT CC -3’ 
  
The sequence of BRCA1 Gene Nucleotide Base in determining C61G mutation can be downloaded in the 
National Center for Biotechnology (NCBI) Gene Bank and accessed by using code through 
http://www.ncbi.nlm.nih.gov website. The primer can be selected by considering the requirement of a 
primer and paying attention to the location of C61G allele polymorphism which can be known with Avaff 
restriction enzyme. The selective primer pair has the sequence of 5’- CTC TTA AGG GCA GTT GTG AG -3’for 
C61G primer (forward) and 5’- TTC CTA CTG TGG TTG CTT CC -3 for C61G primer (reverse).  
4. Research result & discussion 
Table 2: The differences of laboratory indices in the age group < 50 years  and > 50 years old of normal 
subjects. 
Variable levels concentration based on age 
 < 50 yr > 50 yr 
Estradiol (pg / dl) 106.9±95.8  25.6±34.8 
Cholesterol (mg/dl) 151.1±84,6 140.0±89.0 
Triglyceride (mg/dl) 108.65±93,48 92.4±74.0 
HDL-cholesterol (mg/dl) 30.15±15,1 30.9±20.1 
LDL-cholesterol (mg/dl) 98.85±61,4 90.6±57.5 
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Based on  statisticaly result  table 2 shows on breast cancer women in the aged  < 50 years  that estradiol 
concentration increased difference in the aged  > 50 years and on the same condition followed with the  
decreased cholesterol , Trygliserida and HDL- cholesterol to be low too in the age < 50 years  difference in the 
age  > 50 years.  
Chi-square examination between for two group results  with  p < 0.04 ( p <0.05). 
Table 3: The Difference of estradiol levels and HDL-cholesterol levels between of Subjects with breast cancer 
Variables Age Group 
 
< 50 yr > 50 yr 
Estradiol (pg /dl) 106.9±95.8  25.6±34.8 
HDL cholesterol(mg/dl) 30.4±15.1 32.1±18.7 
 
Estradiol concentration  increased in the aged group  40-49 years  and decreased in the age group  50-59 yr.  
HDL- cholesterol in the aged group 40-49 years and 50-59 years to be decreased. In the aged  <  50  years 
estradiol concentration to be decreased  and in the aged   >  50  years estradiol to be low and HDL – cholesterol 
increased in the aged   >  50 years. 
Table 4: Estradiol dan Lipid Profile between normal and breast cancer women 
  
Group I  Group II  Group III  Group IV  
Normal BC Normal BC Normal BC Normal BC 
Estradiol(pg/dl) 47.9±20 98.3±67,48 48.8±21 114.2±107.2 8.6±4.2 33.4±43.98 3.2±1.5 18.9±9 
Total cholesterol 
(mg/dl) 
201±38 139,2±74 208±40 151.0±91.7 234±63 120±97.7 240±42 171.6±68.9 
HDL chol l(mg/dl) 56±5 32.2±15.8 52±14 28.6±15.3 47±10 25.9±21.6 39±15 38.3±15.7 
LDL chol (mg/dl) 129±38 86.6±53.6 131±55 101.2±66 156±60 78.2±63.7 160±36 111±44.6 
Group I, 30 – 39 years  Group  II, 40 – 49 years   Group III, 50 – 59 years Group IV,>  60 years 
BC, breast cancer  
It was found that in normal patients the estradiol content which decreased significantly between the age group of 
40-49 years with the content of 48.8 ± 21 ng/ml and the age group of 50-59 years with the content of 8.6 ± 4.2 
pg/m [6,7]. Table 4 demonstrate the differences in the age groups II and III, in which the was the decrease in 
estradiol content from 40-49 years (114 ± 107.2) to 50-59 years (22.4 ± 43.98),  the differences was significant 
between pre-menopause and menopause. Syukur and his colleagues found the difference of HDL levels among 
normal patients. There was significant decrease in HDL –cholesterol levels in the age group of 30-39 years, 40-
49 years, and 50-59 years with the content value of 56 ± 5 mg/dl, 52 ± 14 mg/dl, and 39 ± 15 mg/dl respectively. 
While in breast cancer patients this condition was also found in the age group of 30-39 years (32.2 ± 15.8), 40-
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49 years (28.6 ± 15.3), and 50-59 years (25.9 ± 21.6) which decreased so that there was significant difference 
between pre-menopause and menopause.   Therefore, it could be concluded that there was the correlation of 
Group II with Group III toward the incidence of breast cancer which was associated with the increase in ages 
with estradiol content and HDL-cholesterol content.    Current research the correlation of body weight with 
breast cancer was not obvious or in negative stage, the low level of HDL-cholesterol had been associated with 
the risk for breast cancer. The 27-hydroxycholesterol (27HC) could function as estrogens and could increase the 
proliferation of breast cancer cells in ER (+). High cholesterol, and LDL  became obesity co-morbidity which 
was probably the independent risk factor for breast cancer, and the mechanism of pathology in which it was 
based had made it relatively new to be defined [7,8,9].             The incidence of breast cancer rarely occurs in a 
person who is below 30 years old  in accordance with multistep cancer progression model of Knudson [10,11].  
The decrease in HDL-cholesterol in the age group of > 50 years was related to the period of menopause and to 
the post-menopause. The older a person is, the more he has the risk for being affected by cancer. Breast cancer 
usually occurs in women who are over 50 years old and who have undergone menopause. About 80% of the 
cases in breast cancer occur in women who are over 50 years old. In the post-menopause women, the risk factor 
for obesity can increase the incidence of breast cancer with positive Estrogen Receptor (ER) of > 50% where the 
obesity population in the United States is > 40% and it increases rapidly in women over 60 years old. 
Supplementary independent risk factor for breast cancer occurs in women in the post-menopause in which 
morbidity with obesity exists; it can also cause damage/change in cholesterol metabolism [12,13]. In the pre-
menopause women, about two-thirds of women who suffer from breast carcinoma are < 50 years old who have 
positive ER expression.   
Table 7: The Difference in the aged group and reseptor  ER/PR  Receptor in the breast cancer  women  
 
 
Ages 
 ER+/PR+ ER+/PR- ER-/PR+ ER-/PR- 
I 30-39 years 3 0 2 1 
II 40-49 years 6 0 4 6 
III 50-59 years 2 0 2 3 
IV >60 years 2 3 1 5 
 
Total  13 3 9 15 
 
Persentase 32.5% 7.5% 22.5% 37.5% 
 
Multiple positive tumors (55% to 65% of breast cancer) have better prognosis and response to hormonal 
therapy. This group is also associated with older age, lower level, smaller size tumor, and lower mortality.  
Multiple negative tumors which are the second biggest group (18-25%), 85% of them are level 3 tumor; it is 
related to high recurrence level, low resistance, and unresponsive to hormonal therapy. Mean while, for single 
positive group, the consequences of ER+/PR- (12-17 %) and ER-/PR+ (1-2%) are not understood well. This 
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group can be related to high level of histopathology, bad prognosis, and big size tumor [13].  
Table 8: The Difference between Age Group and HER-2/neu Receptors in each Age Group in the Age of Breast 
Cancer Cases 
 Umur HER-2/neu(+1) HER-2/neu (+2) HER-2/neu(+3) 
I 30 – 39 yr 1 1 5 
II 40 – 49 yr 1 0 8 
III 50 – 59 yr 0 0 4 
IV >60 yr 0 2 3 
 Persentase 5,5% 8,3% 55,5% 
 
Human epidermal growth factor receptor-2 onkogene ERBB2 (which is commonly called as HER-2) encodes 
epidermal growth factor receptor (EGFR) family from tyrosine kinase and is located in chromosome 17q21. The 
gene is very important for differentiation, adhesion, and motility cells. HER-2 is positive in about 18-20% of 
breast cancer. Positive HER-2 is commonly associated with bad differentiation, metastasis to lymph nodes, 
recurrences, and high mortality rate so that it has bad prognosis.   
Other researchers point out that high HER-2/neu expression is associated with high level of histopathology, 
decreasing resistance, decreasing response to methotrexate and hormonal receptor modulators, and increasing 
response to dexorubicin. It is also associated with bigger size tumor, metastasis to lymph nodes, and worse 
resistance. 
The risk for being affected by breast cancer a woman who is 50 years old and who will have the risk for being 
affected by breast cancer in all her life is 11%, while a woman who is 70 years old and who will have the risk 
for being affected by breast cancer is only 7% [13.14].  In the following research on Polish female population 
with breast and ovarian cancers with the history of family, it was found that there were three BRCA1 genes 
which were mutated; some of the important ones had been detected, including 538insG, 185delAG, and C61G in 
exons 20.2 and 5 [14]. 
5. Conclusion 
From the explanation of the Tables above, it could be concluded that 
1. Age groups II-III (40-60 years old) were the period of breast cancer development which was associated 
with the drastic decrease in estradiol hormone and in HDL-cholesterol; 
2. This condition was correlated with the age group of pre-menopause, menopause, and post-menopause; 
3. There was no SNP polymorphism, due to the differences in location, race, lifestyle, and environment. 
The next stage was the examination of PCR DNA in cancer tissues/blood and sequencing. Based on the analysis 
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on the result of sequencing, it was found that there was no mutation or polymorphism in the SNP. Of the 35 
samples which had been analyzed, all of them had normal alleles (wild type).  
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